Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation.

Trial Profile

Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary)
  • Indications Kidney-pancreas transplant rejection; Pancreas transplant rejection; Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 29 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
    • 29 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top